Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Jeremy S Abramson, M Lia Palomba, Leo I Gordon...
https://pubmed.ncbi.nlm.nih.gov/32888407/Actively Recruiting
Led by Tel-Aviv Sourasky Medical Center · Updated on 2026-05-01
12
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are evaluating the safety of a combination treatment using CLS-015 with anti-CD19 CAR-T cell therapy in patients with large B-cell lymphoma who have stable or progressive disease during lymphodepletion. This Phase 1, single-center, open-label study aims to improve clinical response by reversing negative effects of neutrophil extracellular traps NETs on immune function and CAR-T cells, addressing the high risk of early disease progression in these patients. Participants will receive CLS-015 as an intravenous infusion on days 0, 3, 6, 10, and 15 after the CAR-T cell infusion. CLS-015 is being studied for its potential to enhance CAR-T cell activity, prevent T-cell exhaustion, reduce cytokine release syndrome, and improve CAR-T penetration into lymphoma areas by enzymatically breaking down NETs. All enrolled patients with stable or progressive disease during lymphodepletion will receive this treatment schedule. During the study, participants will be closely monitored with blood tests and evaluations for cytokine release syndrome, neurotoxicity, HLH-like syndrome, and cytopenias. Follow-up visits occur daily for 15 days after CAR-T infusion, then twice weekly for another 15 days, with additional checkups at 2, 6, 9, and 12 months post-infusion. The study will assess safety and tolerability over an average of two years from treatment start.
CONDITIONS
Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.
R
Ron Ram, Prof.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tel-Aviv Sourasky Medical Center
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Duration - Approximately 15 days after CAR-T infusion
Participants receive CLS-015 intravenous infusions on Days 0, 3, 6, 10, and 15 after CAR-T cell infusion.
5 infusion visits
Duration - Up to 12 months post CAR-T infusion
Participants are followed for safety monitoring including blood tests and assessment of cytokine release syndrome, neurotoxicity, HLH-like syndrome, and cytopenias.
Daily visits for 15 days, then twice weekly visits for 15 days, plus visits at 2, 6, 9, and 12 months post CAR-T infusion
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Jeremy S Abramson, M Lia Palomba, Leo I Gordon...
https://pubmed.ncbi.nlm.nih.gov/32888407/Hossein Borghaei, Scott Gettinger, Everett E Vokes...
https://pubmed.ncbi.nlm.nih.gov/33449799/Man Nie, Linbin Yang, Xiwen Bi...
https://pubmed.ncbi.nlm.nih.gov/30446590/Philippe Armand, Andreas Engert, Anas Younes...
https://pubmed.ncbi.nlm.nih.gov/29584546/Tel-Aviv Sourasky Medical Center
Lead Sponsor